Parkinson's disease (PD): treatment of dyskinesias

Evidence-based neurology checklist on parkinson's disease (pd): treatment of dyskinesias: Amantadine: routes of administration Immediate release Extended release Intravenous Amantadine: side effects Other potential anti-dyskinesia drugs Other treatments

Amantadine: routes of administration

  • Immediate release
  • Extended release
  • Intravenous

Amantadine: side effects

Other potential anti-dyskinesia drugs

Other treatments

References

  1. Rascol O, Fabbri M, Poewe W. Amantadine in the treatment of Parkinson's disease and other movement disorder. Lancet Neurol 2021; 20:1048-1056. 
  2. Pahwa R, Factor SA, Lyons KE, et al. Practice parameter: treatment of Parkinson disease with motor fluctuations and dyskinesia (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2006; 66:983-995.
  3. Perez-Lloret S, Rascol O. Efficacy and safety of amantadine for the treatment of L-DOPA-induced dyskinesia. J Neural Transm (Vienna) 2018; doi: 10.1007/s00702-018-1869-1 (Epub ahead of print).
  4. Oertel W, Eggert K, Pahwa R, et al. Randomized, placebo-controlled trial of ADS-5102 (amantadine) extended-release capsules for levodopa-induced dyskinesia in Parkinson's disease (EASE LID 3). Mov Disord 2017; 32:1701-1709.
  5. Kong M, Ba M, Ren C, Yu L, Dong S, Yu G, Liang H. An updated meta-analysis of amantadine for treating dyskinesia in Parkinson's disease. Oncotarget 2017; 8:57316-57326.
  6. And 2 more. Subscribe to see the full list

Related checklists

Loading...